Molecular Partners

Molecular Partners will present pipeline updates and its 2025 outlook at the J.P. Morgan Healthcare Conference. CEO Patrick Amstutz will discuss advancements in their novel DARPin drug technology, focusing on oncology. The presentation, webcast live, is expected to detail clinical progress, strategic direction, and financial projections for the coming year, offering insights into the company’s innovative therapeutic approach and market potential.